Shannon Briar
Psychiatric/Mental Health · Corbin, KYNPI 1962771626
Payments from drug & device makers
Across 134 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$436
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$410
- Teva Pharmaceuticals USA, Inc.$366
- AbbVie$263
- Johnson & Johnson$205
- Lundbeck LLC$183
- plus $571 from 11 others
What the payments were for
- Food & beverage$2,434100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$125
How this compares
$2,434 in reported general payments places this provider in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 14 | $20,195 |
| CaplytaLumateperone Tosylate | 11 | $17,985 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $16,709 |
| TrintellixVortioxetine Hydrobromide | 17 | $8,138 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 13 | $2,908 |
| Lisdexamfetamine Dimesylate | 11 | $2,693 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 34 | $2,307 |
| Oxcarbazepine | 41 | $2,085 |
| Perphenazine | 12 | $1,609 |
| Fluoxetine Hcl | 41 | $1,420 |
| Fluvoxamine Maleate | 47 | $1,215 |
| Pregabalin | 46 | $1,078 |
| Quetiapine Fumarate | 78 | $692 |
| Prazosin Hcl | 31 | $471 |
| Duloxetine Hcl | 20 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $436 | $20,19514 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $410 | $17,98511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $70 | $8,13817 claims |
| Almatica Pharma LLCSertraline Hcl | $46 | $22137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Corbin
- Timothy CouchCorbin$20K
- Holly SteelyCorbin$7K
- Josephine OwensCorbin$7K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.